中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2010年
3期
303-304
,共2页
膀胱上皮癌%COX-2%诊断
膀胱上皮癌%COX-2%診斷
방광상피암%COX-2%진단
Bladder urothelial carcinoma%COX-2%Diagnosis
目的 探讨血清环氧化酶-2(COX-2)定量测定在膀胱尿路上皮细胞癌(BUC)诊断及随访中的应用价值.方法 采用酶联免疫测定(EIA)法定量测定95例经病理确诊为BUC患者血清中COX-2含量,WHO分级G_1 48例,G_2 39例,G_3 8例.TNM分期Tis及Ta 9例,T_1 33例,T_2 25例,T_3 20例,T_4 8例.40例BUC术后经膀胱镜复查阴性患者、20例癌前病变患者(膀胱黏膜白斑14例,腺性膀胱炎6例)、35例其他泌尿系疾病患者及60例健康对照者进行检测.结果 BUC组血清中COX-2含量为(1.91±0.65)mg/L,显著高于其他组;COX-2在表浅(Tis+Ta+T_1)与侵袭BUC(T_2+L_3+T_4)含量(1.40±0.71)mg/L与(2.38±1.18)ms/L,G_1G_2与G_3含量分别为(1.29±0.51)mg/L、(2.13±0.69)ms/L与(2.33±0.81)mg/L,COX-2含量随BUC分期、分级增高而增加,初发(1.80 ±0.81)mg/L与复发(1.81±1.02)ms/L肿瘤间COX-2含量差异无统计学意义(P＞0.05).结论 BUC患者血清中COX-2水平测定有可能成为一项BUC诊断和术后监测的指标.
目的 探討血清環氧化酶-2(COX-2)定量測定在膀胱尿路上皮細胞癌(BUC)診斷及隨訪中的應用價值.方法 採用酶聯免疫測定(EIA)法定量測定95例經病理確診為BUC患者血清中COX-2含量,WHO分級G_1 48例,G_2 39例,G_3 8例.TNM分期Tis及Ta 9例,T_1 33例,T_2 25例,T_3 20例,T_4 8例.40例BUC術後經膀胱鏡複查陰性患者、20例癌前病變患者(膀胱黏膜白斑14例,腺性膀胱炎6例)、35例其他泌尿繫疾病患者及60例健康對照者進行檢測.結果 BUC組血清中COX-2含量為(1.91±0.65)mg/L,顯著高于其他組;COX-2在錶淺(Tis+Ta+T_1)與侵襲BUC(T_2+L_3+T_4)含量(1.40±0.71)mg/L與(2.38±1.18)ms/L,G_1G_2與G_3含量分彆為(1.29±0.51)mg/L、(2.13±0.69)ms/L與(2.33±0.81)mg/L,COX-2含量隨BUC分期、分級增高而增加,初髮(1.80 ±0.81)mg/L與複髮(1.81±1.02)ms/L腫瘤間COX-2含量差異無統計學意義(P＞0.05).結論 BUC患者血清中COX-2水平測定有可能成為一項BUC診斷和術後鑑測的指標.
목적 탐토혈청배양화매-2(COX-2)정량측정재방광뇨로상피세포암(BUC)진단급수방중적응용개치.방법 채용매련면역측정(EIA)법정량측정95례경병리학진위BUC환자혈청중COX-2함량,WHO분급G_1 48례,G_2 39례,G_3 8례.TNM분기Tis급Ta 9례,T_1 33례,T_2 25례,T_3 20례,T_4 8례.40례BUC술후경방광경복사음성환자、20례암전병변환자(방광점막백반14례,선성방광염6례)、35례기타비뇨계질병환자급60례건강대조자진행검측.결과 BUC조혈청중COX-2함량위(1.91±0.65)mg/L,현저고우기타조;COX-2재표천(Tis+Ta+T_1)여침습BUC(T_2+L_3+T_4)함량(1.40±0.71)mg/L여(2.38±1.18)ms/L,G_1G_2여G_3함량분별위(1.29±0.51)mg/L、(2.13±0.69)ms/L여(2.33±0.81)mg/L,COX-2함량수BUC분기、분급증고이증가,초발(1.80 ±0.81)mg/L여복발(1.81±1.02)ms/L종류간COX-2함량차이무통계학의의(P＞0.05).결론 BUC환자혈청중COX-2수평측정유가능성위일항BUC진단화술후감측적지표.
Objective To explore the applied value of quantitative examination of cyclooxygenase2(COX-2)in the serum of patients with bladder urothelial carcinoma(BUC)for diagnosis and follow-up.Methods Serum samples of 95 BUC patients identified by pathology were examined by the quantitative enzyme-linked immunoadsordent assay(EIA).There were 48,39 and 8 cases of WHO grading of G_1,G_2 and G_3,respectively.There were 9,33,25,20 and 8 cases of TNM staging of Tis or Ta,T_1,T_2,T_3 and T_4 respectively.There were 40 cases that underwent surgical procedure previously for BUC but now free by cystoscope of the disease,20 cases of pre-cancerous lesions(including 14 cases of bladder leukoplakia and 6 cases of cystitis glandularis).Thirty-five cases of other urological diseases and 60 healthY volunteers were examined as the matched control groups.Results The level of COX-2 in BUC group was(1.91±0.65)mg/L.significantly higher than other groups.The levels of COX-2 in superficial and invasive BUC were (1.40 ±0.71)and(2.38±1.18)mg/L.The levels of COX-2 in G_1,G_2 and G_3 were(1.29±0.51),(2.13±0.69)and(2.33±0.81)mg/L.respectively.The levels of COX-2 were increased with tumor grade and stage progression.There was no significant difference in the levels of COX-2 between the primary tumors[(1.80±0.81)mg/L]and recurrenttumors[(1.81±1.02)mg/L].Conclusion Serum EIA detection of COX-2 may be a new useful means for diagnosis and postoperative monitoring of BUC patients.
